Navigation Links
Derycz Scientific Hires AstraZeneca Executive to Drive Global Sales Growth

SANTA MONICA, Calif., May 31, 2011 /PRNewswire/ -- Derycz Scientific, Inc., (OTC BB: DYSC), a company pioneering a fresh way of facilitating information flow from content publishers to enterprise customers and their constituents, today announced the appointment of Armand Brevig as Global Sales Director with responsibility for customer retention, new customer acquisition, and sales distribution channels. Mr. Brevig will be based in the United Kingdom and report to Chief Executive Officer (CEO) Peter Derycz, who previously managed the company's sales activities and will continue serving as the company's Chairman and CEO.

"Armand is an expert within the Information Services and Pharmaceutical industries, possessing a keen understanding of customer needs as a result of his unique experiences working in influential positions on both the buyer and supplier side of the business," said Derycz. "As the company's first ever Global Sales Director, Armand will have an immediate impact on our global sales capabilities, strategic planning, and innovation, and will be tasked with doubling our sales force."

Mr. Brevig was most recently the Global (Content Procurement) Category Leader at AstraZeneca, which reported $33.27 billion in 2010 annual revenues. In this position, Mr. Brevig led the creation of the first global Strategic Information Services Sourcing group, led a global multimillion-dollar cross-cultural reprint (scientific journal articles) project, and influenced business process outsourcing (BPO) strategies.

Prior to his most recent position at AstraZeneca, Mr. Brevig was Global Lead (Information) Buyer at AstraZeneca.  He has also worked as a Senior Supplier Account Manager (Market Data Acquisition) at Thomson Financial, Supplier Account Manager (Market Data) at Thomson Financial, Programme Officer (Stationed in Zambia) at United Nations Industrial Development Organization, and Acting UNIDO Office Manager (Zambia) at United Nations Industrial Development Organization.  Mr. Brevig is fluent in French, German, Danish and English.

For more information about Derycz Scientific, visit    

About Derycz Scientific®

Derycz Scientific, Inc. develops companies, products, services and systems that facilitate the re-use of published content in a manner that helps organizations achieve their marketing, communication and research goals effectively and in compliance with copyright law and regulatory rules.  Its subsidiary companies include Reprints Desk, Inc., Pools Press, Inc. and the newly acquired Techniques Appliquees aux Arts Graphiques, S.p.A. (TAAG).  Reprints Desk offers a one-stop solution for reprints, ePrints and single articles, and has delivered millions of articles worldwide.  Reprints Desk is an innovator in content retrieval and ePrint delivery, with services designed to help make effective use of published articles in a copyright-compliant manner.  Pools Press has excelled in the reprint market for more than 30 years.  It provides professionally printed articles from medical and technical journals; prints booklets, catalogs, pamphlets, direct mail pieces and newsletters; and works with publishers who wish to outsource a portion of or all of their reprints business.  TAAG offers printing, distribution and information logistics services, with core competencies in the professional production and distribution of clinical trial kits and clinical article reprints for the life sciences industry.  For more information, please visit

Forward-Looking Statements

Certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in obtaining new customers; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; the Company's success in integrating acquired entities and assets, and all the risks and related information described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"), including the financial statements and related information contained in the Company's Annual Report on Form 10-K.  The Company assumes no obligation to update the cautionary information in this release.

SOURCE Derycz Scientific, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Derycz Scientific CEO Named to PharmaVoice 100 for 2010
2. Derycz Scientific to Exhibit at Digital Pharma West and Digital Pharma East
3. Derycz Scientific Featured in Pharmaceutical Manufacturing and Genetic Engineering & Biotechnology News
4. Derycz Scientific Featured In DDN (Drug Discovery News)
5. Boston Scientific Announces Voluntary Recall of iCross™ Coronary Imaging Catheters
6. American Scientific Resources, Inc. Announces Dismissal of Sanomedics International Holdings, Inc. lawsuit
7. Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System
8. American Scientific Resources, Inc. Announces Quarterly Results
9. ARX-01 and ARX-03 Clinical Results Presented at the 30th Annual Scientific Meeting of the American Pain Society
10. The Board of Directors of Kinex Pharmaceuticals Appoints Dr. David Hangauer as Chief Scientific Officer
11. Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation
Post Your Comments:
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
Breaking Medicine Technology:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):